Being told you have low-risk prostate cancer is often reassuring. Many men are advised that their cancer is slow-growing and that favourable intermediate-risk prostate cancer is often reassuring. Many men are advised that their cancer is slow growing and that active surveillance (careful monitoring rather than immediate treatment) is a safe option.
However, a common and very reasonable question remains:
Could my tests have underestimated how serious my prostate cancer really is?
This article explains, in simple terms, why prostate biopsy and MRI are not perfect, what doctors mean by "upgrading," and where newer imaging, such as PSMA PET scans, may help in selected situations.
Why prostate biopsies do not always show the full picture
A prostate biopsy involves taking small tissue samples from the prostate using needles. Even when done carefully, a biopsy can only sample a small proportion of the gland.
This means:
- The biopsy does not examine the entire prostate
- More aggressive areas can occasionally be missed
- Cancer can appear less serious than it truly is
Large studies indicate that around 25–30% of men are found to have a higher cancer grade at surgery than was seen on their biopsy. This is called under-grading.
This phenomenon does not mean the biopsy was done incorrectly. It reflects the fact that prostate cancer can be patchy, with areas of different aggressiveness within the same gland.
Can MRI scans miss clinically significant prostate cancer?
MRI (magnetic resonance imaging) has greatly improved prostate cancer diagnosis. It helps doctors target suspicious areas and reduces unnecessary biopsies.
However, MRI is not perfect.
Research shows that:
- MRI can miss up to 20% of clinically significant prostate cancers
- MRI focuses on structure, not behaviour
- Some aggressive cancers do not have a typical MRI appearance
An MRI scan showing “no significant abnormality” does not guarantee that aggressive cancer is absent. This is especially relevant when MRI findings do not fully match PSA levels or biopsy results.
What does “upgrading” after prostate surgery actually mean?
Upgrading refers to a situation where prostate cancer appears more aggressive on final surgical analysis than it did on biopsy.
For example:
- Biopsy shows Gleason 3+4
- The surgical specimen shows Gleason 4+3
This matters because higher-grade cancer is more likely to grow and spread.
Importantly:
- Upgrading is common
- It does not mean the cancer suddenly changed
- It means the biopsy did not capture the most aggressive area
Understanding this helps explain why doctors sometimes recommend further assessment even when initial results seem reassuring.
Why accurate grading matters for active surveillance decisions
Active surveillance is a well-established and safe approach for many men with low-risk and selected intermediate-risk prostate cancer.
However, its safety depends on accurate grading and staging.
The main concern is not that surveillance itself is unsafe but that a small number of men may have more aggressive disease than initially detected.
This is why careful selection, structured follow-up, and confidence in the original diagnosis are essential parts of modern prostate cancer care.
What is a PSMA PET scan, and how does it differ from an MRI?
A PSMA PET scan is a type of advanced imaging that looks at biological activity, not just anatomy.
PSMA stands for prostate-specific membrane antigen, a protein commonly found in higher amounts on prostate cancer cells.
Unlike MRI:
- MRI shows what the prostate looks like
- PSMA PET highlights areas where cancer cells are more biologically active
This difference is important when biopsy and MRI results do not fully explain the clinical picture.
Can PSMA PET scans identify prostate cancer that was undergraded?
Emerging research suggests that PSMA PET scans may help identify cancer that behaves more aggressively than expected.
Key observations include:
- Higher PSMA uptake is associated with higher-grade cancer
- Strong uptake in men labelled as Gleason 3+4 is often linked to upgrading at surgery
- High uptake may indicate disease beyond what biopsy alone has shown
This does not mean PSMA PET replaces biopsy. Instead, it may act as an additional layer of information in selected cases where there is concern that the cancer has been underestimated.
Why combining PSMA PET and MRI may improve risk assessment
Recent research suggests that combining PSMA PET with MRI improves the detection of clinically significant prostate cancer compared with MRI alone.
This combined approach can be particularly advantageous when:
- MRI findings are equivocal
- PSA levels appear higher than expected
- Biopsy results do not align with clinical risk factors
The value lies in greater confidence, rather than replacing established tests.
Does this mean PSMA PET should replace biopsy?
No.
It is important to be clear and balanced:
- PSMA PET does not replace prostate biopsy
- It is not a screening test
- It cannot confirm cancer on its own
Biopsy remains essential for diagnosis and grading.
PSMA PET may help in selected situations, but it does not remove the need for tissue confirmation.
Does this mean active surveillance is unsafe?
No.
Active surveillance remains very safe for appropriately selected men.
The potential role of newer imaging is to:
- Improve confidence that surveillance is appropriate
- Identify men who may have been underclassified.
- Reduce uncertainty in borderline cases
For many men, PSMA PET provides reassurance, not escalation.
When might additional imaging be considered — and when is it not?
Additional imaging, such as PSMA PET, may be discussed when:
- PSA, MRI, and biopsy results do not align
- There is concern about possible under-grading
- A man is borderline for active surveillance eligibility
- Anxiety remains high despite reassuring standard tests
However, it is not routinely needed for all men with low-risk or intermediate-risk prostate cancer.
When is PSMA PET unlikely to add value?
PSMA PET is usually not helpful:
- As a replacement for biopsy
- As a general screening test
- In clearly low-risk disease with consistent findings
- When used in isolation without clinical context
Used indiscriminately, it may increase confusion rather than clarity.
What do current guidelines say?
Current international guidelines strongly support PSMA PET for staging higher-risk prostate cancer.
Its role in diagnosis, biopsy pathways, and surveillance is still evolving. Ongoing studies are helping define where it adds genuine clinical value.
For now, its use in this setting should be selective and thoughtful, not routine.
What this means for men worried about missed or underestimated prostate cancer
If you're worried that your prostate cancer is more aggressive than tests show, you're not being unreasonable.
Modern care recognises that:
- Biopsy and MRI are excellent but imperfect
- Under-grading can occur
- Newer imaging may help clarify uncertainty in selected cases
The goal is not to overtreat but, but to ensure decisions are based on the most accurate understanding of the disease.
For many men, reassurance comes from knowing that a careful evaluation has been performed— and that treatment decisions are guided by evidence, balance, and individual risk rather than fear.
